Navigation Links
Researchers identify agent responsible for protection against early stages of atherosclerosis
Date:12/12/2011

(Boston) - Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol. The findings, which appear on-line in Circulation, may have significant public health implications.

Adenosine is a metabolite produced naturally by cells at low levels, and at higher levels during exercise or stress. Adenosine binds to and activates cell surface receptors, one of which is the A2bAR. Previous studies have described the A2bAR as anti-inflammatory and protective against kidney ischemia, cardiac reperfusion injury and restenosis, typically via bone marrow cell signals.

In mouse models, BUSM researchers found atherosclerosis induced by a high-fat diet was more pronounced in the absence of the A2bAR. They also found bone marrow transplantation experiments indicated that A2bAR bone marrow cell signals alone were not sufficient to elicit this effect. "A2bAR genetic ablation led to elevated levels of liver and plasma cholesterol and triglycerides, and to fatty-liver pathology typical of steatosis, assessed by enzymatic assays and analysis of liver sections," explained senior author Katya Ravid, MD, a professor of medicine and biochemistry at BUSM.

The researchers also identified the mechanism underlying this effect in the liver, involving the control of the transcription factor SREBP-1 and its downstream targets-regulators of lipid synthesis. They found restoration of the A2bAR in the liver of A2bAR null mice reduced the lipid profile and atherosclerosis. "Most importantly, in vivo administration of a pharmacological activator of the A2bAR in control mice on a high fat diet reduced lipid profile and atherosclerosis. Thus, this study provides the first evidence that the A2bAR regulates liver hyperlipidemia and atherosclerosis, suggesting that this receptor may be an effective therapeutic target against earlier stages of atherosclerosis," Ravid added.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers use new finding to clear bloodstream malaria infection in mice
2. Penn researchers repair immune system in leukemia patients following chemotherapy
3. Scar findings could lead to new therapies, Stanford researchers say
4. Researchers identify a novel therapeutic approach for liver cancer
5. Researchers design Alzheimers antibodies
6. Toronto researchers obtain detailed molecular signature for Tankyrase
7. Danish mushroom inspires cancer researchers
8. Bone Drugs May Also Battle Breast Cancer, Researchers Say
9. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
10. UCLA researchers suggest unconventional approach to control HIV epidemics
11. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , ... January 19, 2017 ... ... member of the American Osteopathic College of Proctology) announced today the opening ... throughout Southern California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a new ... the benefits of fidgeting to relieve stress and anxiety. No one was more ... Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the popular ...
(Date:1/18/2017)... , ... January 18, 2017 , ... From a health ... released almost daily linking gut health to chronic disease, mental health and general physical ... ” as an important resolution to consider. , For one Charlottesville restaurant, good gut ...
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland Health Care ... a research project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, ... control the disease without compromising normal immune function that often occurs during autoimmune ...
(Date:1/18/2017)... NJ (PRWEB) , ... January ... ... the specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists ... University Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric ... companies developing medical devices for children. The Consortium ... receive seed grants of $50,000 each. The devices ... weak nerve signals, a hand-operated rapid blood delivery system for ... in babies. ...
Breaking Medicine Technology: